Sugi Predict

Sugi Predict / Targets / GRIA3

GRIA3

Glutamate receptor 3 · P42263 · GRIA3 on Sugi Atlas →

29,014 patent compounds predicted against GRIA3, 18,310 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Fanapanel Fanapanel (SCHEMBL353357) 0.51 11/20
Nbqx Nbqx (SCHEMBL120375) 1.00 8/20
SCHEMBL28559 SCHEMBL28559 0.45 6/20
SCHEMBL28560 SCHEMBL28560 0.45 6/20
(R,S)-Ampa (R,S)-Ampa (SCHEMBL68799) 0.69 5/20
SCHEMBL43843 SCHEMBL43843 0.44 5/20
SCHEMBL158168 SCHEMBL158168 0.44 5/20
SCHEMBL121942 SCHEMBL121942 0.64 4/20
SCHEMBL195083 SCHEMBL195083 0.61 4/20
SCHEMBL38535 SCHEMBL38535 0.47 4/20
SCHEMBL287393 SCHEMBL287393 0.47 4/20
SCHEMBL287394 SCHEMBL287394 0.47 4/20
SCHEMBL147829 SCHEMBL147829 0.56 3/20
SCHEMBL123451 SCHEMBL123451 0.55 3/20
SCHEMBL156953 SCHEMBL156953 0.50 3/20
SCHEMBL205449 SCHEMBL205449 0.50 3/20
SCHEMBL205450 SCHEMBL205450 0.50 3/20
SCHEMBL118018 SCHEMBL118018 0.44 3/20
SCHEMBL197230 SCHEMBL197230 0.43 3/20
SCHEMBL197231 SCHEMBL197231 0.43 3/20

Clinical trials — most relevant to GRIA3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine PHASE4COMPLETED
Ketamine Treatment Effects on Synaptic Plasticity in Depression PHASE4COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders PHASE3RECRUITING
Memantine for Refractory OCD Patients PHASE3UNKNOWN
Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers PHASE3COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia PHASE2UNKNOWN
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia PHASE2COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder PHASE2COMPLETED
Brain Imaging, Genetics and Treatment for Major Depression PHASE1WITHDRAWN
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203 PHASE1COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Antidepressant Effects of NR2B in Major Depression PHASE1COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
D-aspartate and Therapeutic Exercise EARLY_PHASE1UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy nanUNKNOWN
Acamprosate: Genes Associated With Response nanCOMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Genetic Variants Associated With Adolescent Suicide Attempts nanCOMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX nanCOMPLETED
Genetic Predictors of Lithium Response in Bipolar Disorder nanCOMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients nanCOMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome nanUNKNOWN
Metabotropic Receptors For Glutamate Type 3 In Parkinson's nanUNKNOWN
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms nanCOMPLETED
A Positional Cloning Study on Schizophrenia nanCOMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
Epigenetic and Neurochemical Correlates of Bipolar Disorder nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a GRIA3 binder may also engage these)

ProteinNameSimilarity
P19492 — 1.000 P19492 →
Q9Z2W9 — 1.000 Q9Z2W9 →
Q9Z2W8 — 1.000 Q9Z2W8 →
Q38PU6 — 1.000 Q38PU6 →
GRIA2 Glutamate receptor 2 1.000 landscape →
GRIA4 Glutamate receptor 4 1.000 landscape →
Q38PU5 — 1.000 Q38PU5 →
P23819 — 1.000 P23819 →
GRIA1 Glutamate receptor 1 1.000 landscape →
Q5R4M0 — 1.000 Q5R4M0 →
P19491 — 1.000 P19491 →
P19490 — 1.000 P19490 →
Q38PU8 — 1.000 Q38PU8 →
P19493 — 1.000 P19493 →
Q38PU7 — 1.000 Q38PU7 →
P23818 — 0.998 P23818 →
B1AS29 — 0.998 B1AS29 →
P42260 — 0.998 P42260 →
Q38PU2 — 0.997 Q38PU2 →
P42264 — 0.997 P42264 →
P39087 — 0.997 P39087 →
Q91755 — 0.996 Q91755 →
GRIK2 Glutamate receptor ionotropic, kainate 2 0.995 landscape →
Q38PU3 — 0.995 Q38PU3 →
B3LZ39 — 0.994 B3LZ39 →
GRIK3 Glutamate receptor ionotropic, kainate 3 0.994 landscape →
B4MU83 — 0.993 B4MU83 →
P26591 — 0.993 P26591 →
GRIK1 Glutamate receptor ionotropic, kainate 1 0.992 landscape →
A0A2R8QF68 — 0.992 A0A2R8QF68 →